Further evidence for increased macrophage migration inhibitory fator expression in prostate cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Meyer Siegler, Katherine L ^a,b   Iczkowski, Kenneth A ^c,d   Vera, Pedro L ^a,b  

^a Bay Pines VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; B LYMPHOCYTE ANTIGEN; BOVINE SERUM ALBUMIN; HLA ANTIGEN CLASS 2;

ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DENATURING GRADIENT GEL ELECTROPHORESIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; EPITHELIUM; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; INVARIANT CHAIN; MALE; METABOLISM; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SERUM ALBUMIN, BOVINE;

EID: 26844433956     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-73     Document Type: Article

References (36)

1. Bloom BR, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82.
2. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966, 56:72-77.
3. Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-35.
4. Metz CN, Bucala R: Role of macrophage migration inhibitory factor in the regulation of the immune response MIF. Adv Immunol 1997, 66:123-197.
5. Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000, 89:334-341.
6. Bini L, Magi B, Marzocchi B,0 Arcuri F, Tripodi S, Cintorino M: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997, 18:2832-2841.
7. Meyer-Siegler K, Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996, 48:448-452.
8. Nishihira J: Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res 2000, 20:751-762.
9. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999, 5:181-191.
10. Meyer-Siegler KL, Erica Leifheit C, Vera PL: Inhibition of Macrophage Migration Inhibitory Factor Decreases Proliferation and Cytokine Expression in Bladder Cancer Cells. BMC Cancer 2004, 4:34.
11. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J: MIF signal transduction initiated by binding to CD74. J Exp Med 2003, 197:1467-1476.
12. Meyer-Siegler K, Fattor RA, Hudson PB: Expression of macrophage migration inhibitory factor in the human prostate. Diagn Mol Pathol 1998, 7:44-50.
13. Meyer-Siegler KL, Bellino MA, Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 2002, 94:1449-1456.
14. Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D: Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: A re-evaluation. Prostate 2005, 62:34-39.
15. Meyer-Siegler KL, Vera PL: Substance P induced changes in CD74 and CD44 in the rat bladder. J Urol 2005, 173:615-620.
16. Meyer-Siegler KL: Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res 2000, 20:769-778.
17. Zeng FY, Kratzin H, Gabius HJ: Migration inhibitory factor-binding sarcolectin from human placenta is indistinguishable from a subfraction of human serum albumin. Biol Chem Hoppe Seyler 1994, 375:393-399.
18. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI: Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004, 91:459-477.
19. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002, 23:967-975.
20. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS: The association of Id-1, MIF and GSTpi with acquired drug resistance in hormone independent prostate cancer cells. Oncol Rep 2005, 13:983-988.
21. Selby C: Interference in immunoassay. Ann Clin Biochem 1999, 36:704-721.
22. Link RE, Shariat SF, Nguyen CV, Farr A, Weinberg AD, Morton RA: Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004, 171:2234-2238.
23. Kioukia-Fougia N, Christofidis I, Strantzalis N: Physicochemical conditions affecting the formation/stability of serum complexes and the determination of prostate-specific antigen (PSA). Anticancer Res 1999, 19:3315-3320.
24. Sun HW, Bernhagen J, Bucala R, Lolis E: Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1996, 93:5191-5196.
25. Philo JS, Yang TH, LaBarre M: Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys Chem 2004, 108:77-87.
26. Potolicchio I, Santambrogio L, Strominger JL: Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides. J Biol Chem 2003, 278:30889-30895.
27. Vera PL, Iczkowski KA, Leng L, Bucala R, Meyer-Siegler KL: Macrophage migration inhibitory factor is released as a complex with α-1-inhibitor-3 in the intraluminal fluid during bladder inflammation in the rat. J Urol 2005, 174:338-343.
28. Wassler M, Esnard F, Fries E: Posttranslational folding of alpha 1-inhibitor 3. Evidence for a compaction process. J Biol Chem 1995, 270:24598-24603.
29. Gonias SL, Carmichael A, Mettenburg JM, Roadcap DW, Irvin WP, Webb DJ: Identical or overlapping sequences in the primary structure of human alpha(2)-macroglobulin are responsible for the binding of nerve growth factor-beta, platelet-derived growth factor-BB, and transforming growth factor-beta. J Biol Chem 2000, 275:5826-5831.
30. Liu Q, Ling TY, Shieh HS, Johnson FE, Huang JS, Huang SS: Identification of the high affinity binding site in transforming growth factor-beta involved in complex formation with alpha 2-macroglobulin. Implications regarding the molecular mechanisms of complex formation between alpha 2-macroglobulin and growth factors, cytokines, and hormones. J Biol Chem 2001, 276:46212-46218.
31. del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R: Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment- related changes. Prostate 2000, 45:51-57.
32. Arcuri F, del Vecchio MT, de Santi MM, Lalinga AV, Pallini V, Bini L: Macrophage migration inhibitory factor in the human prostate: identification and immunocytochemical localization. Prostate 1999, 39:159-165.
33. Weir EG, Partin AW, Epstein JI: Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000, 163:1739-1742.
34. Stenman U-H, Leinonen J, Zhang W-M, Finne P: Prostate-specific antigen. Semin Cancer Biology 1999, 9:83-93.
35. Wraight CJ, van Endert P, Moller P, Lipp J, Ling NR, MacLennan IC: Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem 1990, 265:5787-5792.
36. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999, 98:296-302.